CA2888160A1 - Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy - Google Patents
Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy Download PDFInfo
- Publication number
- CA2888160A1 CA2888160A1 CA 2888160 CA2888160A CA2888160A1 CA 2888160 A1 CA2888160 A1 CA 2888160A1 CA 2888160 CA2888160 CA 2888160 CA 2888160 A CA2888160 A CA 2888160A CA 2888160 A1 CA2888160 A1 CA 2888160A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- pyrazolo
- ethyl
- pyrimidine
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717429P | 2012-10-23 | 2012-10-23 | |
| US61/717,429 | 2012-10-23 | ||
| PCT/IB2013/059239 WO2014064566A1 (en) | 2012-10-23 | 2013-10-09 | Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2888160A1 true CA2888160A1 (en) | 2014-05-01 |
Family
ID=49765599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2888160 Abandoned CA2888160A1 (en) | 2012-10-23 | 2013-10-09 | Use of a tetrasubstituted pyrazolo[4,3-d]pyrimidine compound for treating diabetic nephropathy |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150274735A1 (https=) |
| EP (1) | EP2911672A1 (https=) |
| JP (1) | JP2015534977A (https=) |
| KR (1) | KR20150056853A (https=) |
| CN (1) | CN104755086A (https=) |
| AU (1) | AU2013336293B2 (https=) |
| BR (1) | BR112015008380A2 (https=) |
| CA (1) | CA2888160A1 (https=) |
| HK (1) | HK1211850A1 (https=) |
| IL (1) | IL238374A0 (https=) |
| IN (1) | IN2015DN03190A (https=) |
| MX (1) | MX2015005004A (https=) |
| RU (1) | RU2015115005A (https=) |
| SG (1) | SG11201502286XA (https=) |
| WO (1) | WO2014064566A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101939328B1 (ko) * | 2012-12-21 | 2019-01-16 | 주식회사 엘지화학 | 신규한 구조를 가지는 중공사막 및 그 제조 방법 |
| EP3925957A4 (en) | 2019-02-15 | 2022-11-02 | Tohoku University | 1,3-DIOXOLANE DERIVATIVE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
| SI1881985T1 (sl) * | 2005-05-12 | 2011-03-31 | Pfizer | Brezvodne kristalinične oblike N-1-(2-etoksietil)-5(N-etil-N-metilamino)-7-(4-metilpriridin-2-il-amino) -1H-pirazolo(4,3-d)pirimidin-3-karbonil"metansulfonamida |
| CA2608018C (en) * | 2005-05-12 | 2010-07-13 | Pfizer Inc. | Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| NL2000291C2 (nl) * | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
-
2013
- 2013-10-09 MX MX2015005004A patent/MX2015005004A/es unknown
- 2013-10-09 RU RU2015115005A patent/RU2015115005A/ru not_active Application Discontinuation
- 2013-10-09 BR BR112015008380A patent/BR112015008380A2/pt not_active IP Right Cessation
- 2013-10-09 EP EP13805563.7A patent/EP2911672A1/en not_active Withdrawn
- 2013-10-09 IN IN3190DEN2015 patent/IN2015DN03190A/en unknown
- 2013-10-09 AU AU2013336293A patent/AU2013336293B2/en not_active Expired - Fee Related
- 2013-10-09 KR KR1020157010146A patent/KR20150056853A/ko not_active Ceased
- 2013-10-09 JP JP2015537386A patent/JP2015534977A/ja active Pending
- 2013-10-09 CA CA 2888160 patent/CA2888160A1/en not_active Abandoned
- 2013-10-09 HK HK15112752.6A patent/HK1211850A1/xx unknown
- 2013-10-09 SG SG11201502286XA patent/SG11201502286XA/en unknown
- 2013-10-09 CN CN201380055135.1A patent/CN104755086A/zh active Pending
- 2013-10-09 US US14/434,236 patent/US20150274735A1/en not_active Abandoned
- 2013-10-09 WO PCT/IB2013/059239 patent/WO2014064566A1/en not_active Ceased
-
2015
- 2015-04-19 IL IL238374A patent/IL238374A0/en unknown
-
2016
- 2016-01-21 US US15/002,530 patent/US20160136170A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014064566A1 (en) | 2014-05-01 |
| US20160136170A1 (en) | 2016-05-19 |
| AU2013336293A1 (en) | 2015-04-09 |
| JP2015534977A (ja) | 2015-12-07 |
| KR20150056853A (ko) | 2015-05-27 |
| MX2015005004A (es) | 2015-07-17 |
| SG11201502286XA (en) | 2015-05-28 |
| CN104755086A (zh) | 2015-07-01 |
| HK1211850A1 (en) | 2016-06-03 |
| BR112015008380A2 (pt) | 2017-07-04 |
| IN2015DN03190A (https=) | 2015-10-02 |
| EP2911672A1 (en) | 2015-09-02 |
| AU2013336293B2 (en) | 2016-05-12 |
| US20150274735A1 (en) | 2015-10-01 |
| RU2015115005A (ru) | 2016-12-20 |
| IL238374A0 (en) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3194395B1 (en) | Sgc stimulators | |
| JP2016540017A (ja) | ｓＧＣ刺激物質 | |
| CZ20023381A3 (cs) | Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor | |
| Sun et al. | Cyclopropyl scaffold: A generalist for marketed drugs | |
| DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
| SG188238A1 (en) | Combination therapy for treating hcv infection | |
| AU716519B2 (en) | Method of treating renal disease using an ace inhibitor and an A II antagonist | |
| CA3096156A1 (en) | Use of inhibitors of bcr-abl mutants for the treatment of cancer | |
| EP1673107B1 (en) | Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker | |
| AU2013336293B2 (en) | Use of a tetrasubstituted pyrazolo(4,3-d)pyrimidine compound for treating diabetic nephropathy | |
| WO2010097501A2 (en) | A combination treatment | |
| JP2006517557A (ja) | 脳卒中発作予防のための、アセチルサリチル酸およびアンジオテンシンｉｉ拮抗薬と組み合わせたジピリダモールの使用 | |
| US20100249103A1 (en) | combination treatment | |
| CN105025895A (zh) | 用于治疗肺动脉高压和肺损伤的1,3-二氢咪唑-2-硫酮衍生物 | |
| CA2870373A1 (en) | Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof | |
| US20090005404A1 (en) | Pyridylsulfonamido pyrimidines for treating diabetic nephropathy | |
| CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
| CA2946151C (en) | Stable solid immunosuppressor composition | |
| WO2011027021A1 (en) | A method for the treatment of hypertension | |
| WO2023225163A1 (en) | Methods of treating focal segmental glomerulosclerosis with atrasentan | |
| JP2008133229A (ja) | 医薬組成物 | |
| HK40030002B (zh) | 癌症疗法 | |
| CN101163705A (zh) | 组合产品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150410 |
|
| FZDE | Discontinued |
Effective date: 20170829 |